Adipocyte-derived FABP4 promotes metabolism-associated steatotic liver–induced hepatocellular carcinoma by driving ITGB1-mediated β-catenin activation
Journal of Clinical Investigation · 15.12.2025 · 135 (24)
DOI: 10.1172/jci182322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.12.2025. Verfasst von Carmen Oi Ning Leung und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, Carcinoma, Hepatocellular, Liver Neoplasms, Integrin beta1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovation and Technology Commission, Research Grants Council, University Grants Committee.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease–induced (MASLD-induced) hepatocellular carcinoma (HCC) is an emerging malignancy linked to excessive accumulation of adipose tissue and hepatic fat. Understanding the role of adipocytes in the development of MASLD-induced HCC is crucial. In an in vitro coculture system, differentiated adipocytes were found to enhance cancer stemness and drug resistance in HCC through paracrine signaling. Fatty acid–binding protein 4 (FABP4) was preferentially secreted by adipocytes, and recombinant FABP4 further augmented the cancer stem cell (CSC) properties of HCC cells. Notably, Fabp4 –/– mice exhibited a marked delay in the progression of MASLD-HCC, which correlated with the increased HCC risk observed in MASLD patients with elevated FABP4 expression. Mass spectrometry analysis identified integrin β 1 (ITGB1) as a binding partner of FABP4. These data, together with a substantial downregulation of the Wnt/β-catenin pathway in Fabp4 –/– mouse tumors, revealed that FABP4 augmented liver CSC functions by activating PI3K/AKT/β-catenin signaling via ITGB1. We developed an anti-FABP4 neutralizing antibody that successfully inhibited FABP4-driven CSC functions and suppressed MASLD-induced HCC. In conclusion, our findings indicate that adipocyte-derived FABP4 plays a critical role in the development of MASLD-induced HCC and targeting the ITGB1/PI3K/AKT/β-catenin signaling cascade may offer a promising approach to combat this aggressive disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.
- Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
- School of Public Health, Sun Yat Sen University, Guangzhou, China.
- Comprehensive Liver Cancer Center, The Fifth Medical Center of PLA General Hospital, Beijing, China.
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine.
- State Key Laboratory of Liver Research, and.
Förderung
- National Natural Science Foundation of China
- Innovation and Technology Commission
- Research Grants Council, University Grants Committee
- Innovation and Technology Fund
Zitieren
APA
Leung, C. O. N., Gurung, S., Chung, K. P. S., Leung, R. W. H., Lei, M. M. L., Chan, M. S. M., Muliawan, G. K., Khan, S. A., Wu, X. Q., Yu, J., Zhu, H. L., Lu, Y. Y., Ma, S., Wu, X., Hoo, R. L. C., & Lee, T. K. W. (2025). Adipocyte-derived FABP4 promotes metabolism-associated steatotic liver–induced hepatocellular carcinoma by driving ITGB1-mediated β-catenin activation. Journal of Clinical Investigation, 135(24). https://doi.org/10.1172/jci182322
Vancouver
Leung CON, Gurung S, Chung KPS, Leung RWH, Lei MML, Chan MSM, et al. Adipocyte-derived FABP4 promotes metabolism-associated steatotic liver–induced hepatocellular carcinoma by driving ITGB1-mediated β-catenin activation. Journal of Clinical Investigation. 2025;135(24). doi:10.1172/jci182322
BibTeX
@article{Leung2025,
author = {Leung, Carmen Oi Ning and Gurung, Shilpa and Chung, Katherine Po Sin and Leung, Rainbow Wing Hei and Lei, Martina Mang Leng and Chan, Mandy Sze Man and Muliawan, Gregory Kenneth and Khan, Shakeel Ahmad and Wu, Xue Qian and Yu, Jun and Zhu, Hui Lian and Lu, Yin Ying and Ma, Stephanie and Wu, Xiaoping and Hoo, Ruby Lai Chong and Lee, Terence Kin Wah},
title = {Adipocyte-derived FABP4 promotes metabolism-associated steatotic liver–induced hepatocellular carcinoma by driving ITGB1-mediated β-catenin activation},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {24},
doi = {10.1172/jci182322}
}
EUVIMED